FDAapproval83% confidence
CDER proposes to withdraw approval of TAVNEOS
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable approval decision relevant to Sandoz.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · Anticonvulsant
- Sub-indication
- General
Related signal: Sandoz's Gabapentin ANDA075428 Receives Abbreviated Approval